Solan Headlines

HR-positive/HER2-negative Breast Cancer Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

HR-positive/HER2-negative Breast Cancer Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

July 21
22:48 2021
HR-positive/HER2-negative Breast Cancer Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

DelveInsight Business Research LLP
DelveInsight’s “HR-positive/HER2-negative Breast Cancer Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the HR-positive/HER2-negative Breast Cancer pipeline landscapes. It comprises HR-positive/HER2-negative Breast Cancer pipeline drug profiles, including clinical and non-clinical stage products.

DelveInsight’sHR-positive/HER2-negative Breast Cancer Pipeline Insight report provides comprehensive insights about key companies and pipeline drugs in the HR-positive/HER2-negative Breast Cancer pipeline landscapes. It comprises HR-positive/HER2-negative Breast Cancer pipeline drug profiles, including clinical and non-clinical stage products. It also includes the HR-positive/HER2-negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive HR-positive/HER2-negative Breast Cancer pipeline products.   

 

Some of the key takeaways of the HR-positive/HER2-negative Breast Cancer Pipeline Report  

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Jiangsu HengRui Medicine, Radius Pharmaceuticals, Immunomedics, Roche, Syndax Pharmaceuticals, Merck Sharp and Dohme, Merck Sharp and Dohme Corp./Eisai, Bayer, etc., are developing therapies for the treatment of HR-positive/HER2-negative Breast Cancer.

  • Emerging therapies such as SHR6390, Elacestrant (RAD1901), Sacituzumab govitecan, Ipatasertib and Venclexta, Entinostat, Pembrolizumab, Eribulin Mesylate, Radium-223 dichloride, are expected to have a significant impact on the  HR-positive/HER2-negative Breast Cancer market in the coming years.

  • The postmenopausal breast cancer market size within the 7MM was found to be USD 6,315.1 million in 2018.

  • The HR-positive/HER2-negative Breast Cancer market size shall increase during the forecast period 2021–2030.

  • Among the 7MM, the US accounts for 80.51% USD of the HR-positive/HER2-negative Breast Cancer market size in 2018. 

Get an overview of pipeline landscape @HR-positive/HER2-negative Breast Cancer Clinical Trials Analysis  

HR-positive/HER2-negative breast cancer is the commonest carcinoma and also accounts for a better percentage of all breast cancers. HR-positive cancer is typically treated with hormone therapies or a combination of hormone therapies with targeted therapy to assist stop tumor growth. 

HR-positive/HER2-negative Breast Cancer Emerging Drugs

  • SHR6390 by Jiangsu HengRui Medicine

  • Elacestrant (RAD1901) by Radius Pharmaceuticals

  • Sacituzumab govitecan by Immunomedics

  • Ipatasertib and Venclexta by Roche

  • Entinostat by Syndax Pharmaceuticals

  • Pembrolizumab by Merck Sharp and Dohme 

  • Eribulin Mesylate by Merck Sharp and Dohme Corp./Eisai   

  • Radium-223 dichloride by Bayer

  • And others.

Scope of HR-positive/HER2-negative Breast Cancer Pipeline Drug Insight

  • Coverage: Global 

  • Major Players: Jiangsu HengRui Medicine, Radius Pharmaceuticals, Immunomedics, Roche, Syndax Pharmaceuticals, Merck Sharp and Dohme, Merck Sharp and Dohme Corp./Eisai, Bayer, and others.

  • Pipeline Therapies: SHR6390, Elacestrant (RAD1901), Sacituzumab govitecan, Ipatasertib and Venclexta, Entinostat, Pembrolizumab, Eribulin Mesylate, Radium-223 dichloride, and others.

Table of Contents

1

HR-positive/HER2-negative Breast Cancer Report Introduction

2

HR-positive/HER2-negative Breast Cancer Executive Summary

3

HR-positive/HER2-negative Breast Cancer Overview

4

HR-positive/HER2-negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5

HR-positive/HER2-negative Breast Cancer Pipeline Therapeutics

6

HR-positive/HER2-negative Breast Cancer Late Stage Products (Phase II/III)

7

HR-positive/HER2-negative Breast Cancer Mid Stage Products (Phase II)

8

HR-positive/HER2-negative Breast Cancer Early Stage Products (Phase I)

9

HR-positive/HER2-negative Breast Cancer Preclinical Stage Products

10

HR-positive/HER2-negative Breast Cancer Therapeutics Assessment

11

HR-positive/HER2-negative Breast Cancer Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

HR-positive/HER2-negative Breast Cancer Key Companies

14

HR-positive/HER2-negative Breast Cancer Key Products

15

HR-positive/HER2-negative Breast Cancer Unmet Needs

16 

HR-positive/HER2-negative Breast Cancer Market Drivers and Barriers

17

HR-positive/HER2-negative Breast Cancer Future Perspectives and Conclusion

18

HR-positive/HER2-negative Breast Cancer Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @HR-positive/HER2-negative Breast Cancer Drugs Pipeline Report

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles